Micro RNAs to Predict Response to Androgen Deprivation Therapy

• Status: Active, not recruiting
• Trial end date: 2023-06-01
• Target enrollment: 0
• Participant gender: Male

Summary

Identify exosomal micro RNA that predict responses to ADT

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical College of Wisconsin
• Treatments: Androgens; Ascorbic Acid; Bicalutamide; Docetaxel; Estrogens, Conjugated (USP); Goserelin; Leuprolide; Methyltestosterone; Triptorelin Pamoate

Criteria

Inclusion Criteria:

• Histologically proven prostate cancer.

• Testosterone level >30ng/ml and at least 6 months since last dose of hormonal therapy.

• History/physical examination including a detailed description of the stage of prostate cancer within 8 weeks prior to registration.

• CT scan of abdomen and pelvis with IV contrast and bone scan should be performed within 8 weeks prior to registration.

• Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.

• Age ≥ 18.

• Patients must provide study-specific informed consent prior to study entry for this project and mandatory blood specimen for banking for future studies (future studies may include genetic testing).

Exclusion Criteria:

• Received hormonal therapy less than 6 months prior to registration.

• History of active secondary malignancy.

• Decline hormone therapy for prostate cancer.

• Current or previous treatment with 5-alpha reductase inhibitors within 6 months prior to enrollment.